Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2017 01:15 ET | Source: Novartis Pharma AG

Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress

Clareon® intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations Congress program highlights Alcon's 70-year legacy of...
September 28, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets

Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and...
September 22, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries

CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has...
September 20, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)

Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM in...
September 16, 2017 10:00 ET | Source: Novartis Pharma AG

Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption

OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost 90%...
September 14, 2017 01:15 ET | Source: Novartis Pharma AG

Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study

51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently...
September 13, 2017 01:15 ET | Source: Novartis Pharma AG

Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data

Cosentyx® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI 90 and...
September 12, 2017 01:15 ET | Source: Novartis Pharma AG

Sandoz proposed biosimilar rituximab accepted for review by the FDA

Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis[1] Sandoz believes the comprehensive data package submitted to the FDA for review confirms...
September 10, 2017 18:05 ET | Source: Novartis Pharma AG

Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma

The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all...
September 09, 2017 05:00 ET | Source: Novartis Pharma AG

Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept

Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD Five-year results from the Lucentis LUMINOUS study, the...